Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic

Journal of Immunological Methods

Volumn 379, Issue 1-2, 2012, Pages 30-41

  Dysinger, Mark ^a   King, Lindsay E ^a  

^a PFIZER INC   (United States)

Author keywords

Bio layer interferometry; Label free; Octet; Sensogram

Indexed keywords

DRUG ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL TISSUE; ARTICLE; BIO LAYER INTERFEROMETRY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INTERFEROMETRY; LIMIT OF QUANTITATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TOXICOKINETICS;

ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFEROMETRY; MACACA FASCICULARIS; RATS; SURFACE PLASMON RESONANCE;

MACACA FASCICULARIS; RATTUS;

EID: 84859776946     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.02.017     Document Type: Article

References (30)

1. Abdiche Y.N., Malashock D.S., Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008, 17(8):1326.
2. Abdiche Y., Malashock D., Pinkerton A., Pons J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal. Biochem. 2008, 15;377(2):209.
3. Avramis V.I., Avramis E.V., Hunter W., Long M.C. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res. 2009, 29(1):299.
4. Baselga J., Pfister D., Cooper M.R., Cohen R., Burtness B., Bos M., D'Andrea G., Seidman A., Norton L., Gunnett K. Phase I studies B. of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000, 18(4):904.
5. Bland J.M., Altman D.G. Measurement in medicine: the analysis of method comparison studies. Statistician 1983, 32:307.
6. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307.
7. Che J., Wang H., Chen Z., Li X., Hou Y., Shan C., Cheng Y. A new approach for pharmacokinetics of single-dose Cetuximab in rhesus monkeys by surface plasmon resonance biosensor. J. Pharm. Biomed. Anal. 2009, 50(2):183.
8. DeSilva, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules 2003.
9. DiGiacomo R.A., Xie L., Cullen C., Indelicato S.R. Development and validation of a kinetic assay for analysis of anti-human interleukin-5 monoclonal antibody (SCH 55700) and human interleukin-5 interactions using surface plasmon resonance. Anal. Biochem. 2004, 327(2):165.
10. Dong Y., Wilkop T., Xu D., Wang Z., Cheng Q. Microchannel chips for the multiplexed analysis of human immunoglobulin G-antibody interactions by surface plasmon resonance imaging. Anal. Bioanal. Chem. 2008, 390(6):1575.
11. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2001, 21(6):1249.
12. Guidi A., Laricchia-Robbio L., Gianfaldoni D., Revoltella R., Del Bono G. Comparison of a conventional immunoassay (ELISA) with a surface plasmon resonance-based biosensor for IGF-1 detection in cows' milk. Biosens. Bioelectron. 2001, 16(9-12):971.
13. Heutmekers T.H., Bremer M.G., Haasnoot W., Nielen M.W. A rapid surface plasmon resonance (SPR) biosensor immunoassay for screening of somatotropins in injection preparations. Anal. Chim. Acta 2007, 586(1-2):239.
14. Kikuchi Y., Unoa S., Nanamia M., Yoshimuraa Y., Iidaa S.-I., Fukushimaa N., Tsuchiyaa M. Determination of concentration and binding affinity of antibody fragments by use of surface plasmon resonance. J. Biosci. Bioeng. 2005, 100:311.
15. Lee J.W., Kelley M., King L.E., Yang J., Salimi-Moosavi H., Tang M.T., Lu J.F., Kamerud J., Ahene A., Myler H., Rogers C. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011, 13(1):99.
16. Li J., Schantz A., Schwegler M., Shankar G. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet® biolayer interferometry. J. Pharm. Biomed. Anal. 2011, 54(2):286.
17. Li L., Schantza A., Schweglerb M., Shankara G. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet® biolayer interferometry. J. Pharm. Biomed. Anal. 2011, 54:286.
18. Lofgren J.A., Dhandapani S., Pennucci J.J., Abbott C.M., Mytych D.T., Kaliyaperumal A., Swanson S.J., Mullenix M.C. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 2007, 178:7467.
19. Lokate A., Beusink J.B., Besselink G., Pruijn G., Schasfoort R. Biomolecular interaction monitoring of autoantibodies by scanning surface plasmon resonance microarray imaging. J. Am. Chem. Soc. 2007, 129(45):14013.
20. Mytych D.T., La S., Barger T., Ferbas J., Swanson S.J. The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J. Pharm. Biomed. Anal. 2009, 49(2):415.
21. Scarano S., Scuffi C., Mascini M., Minunni M. Surface plasmon resonance imaging-based sensing for anti-bovine immunoglobulins detection in human milk and serum. Anal. Chim. Acta 2011, 707(1-2):178.
22. Schmitt H.-M., Brecht A., Piehler J., Gauglitz G. An integrated system for optical biomolecular interaction analysis. Biosens. Bioelectron. 1997, 12(8):809.
23. Stubenrauch K., Wessels U., Birnboeck H., Ramirez F., Jahreis A., Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin. Ther. 2010, 32(9):1597.
24. Szolar O.H., Stranner S., Zinoecker I., Mudde G.C., Himmler G., Waxenecker G., Nechansky A. Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody. J. Pharm. Biomed. Anal. 2006, 41(4):1347.
25. Thway T., Macaraeg C., Calamba D., Patel V., Tsoi J., Ma M., Lee J., DeSilva B. Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: benefits and limitations in assay range. J. Pharm. Biomed. Anal. 2010, 51(3):626.
26. Treviño J., Calle A., Rodríguez-Frade J.M., Mellado M., Lechuga L.M. Determination of human growth hormone in human serum samples by surface plasmon resonance immunoassay. Talanta 2009, 78(3):1011.
27. Viswanathan C.T., Bansal S., Booth B., DeStefano A., Rose M., Sailstad J., Shah V., Skelly J., Swann P., Weiner R. Workshop/conference report - quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007, 9(1):E30.
28. Wong R.L., Mytych D., Jacobs S., Bordens R., Swanson S.J. Validation parameters for a novel biosensor assay which simultaneously measures serum concentrations of a humanized monoclonal antibody and detects induced antibodies. J. Immunol. Methods 1997, 209(1):1.
29. Yang C.Y., Brooks E., Li Y., Denny P., Ho C.M., Qi F., Shi W., Wolinsky L., Wu B., Wong D.T., Montemagno C.D. Detection of picomolar levels of interleukin-8 in human saliva by SPR. Lab Chip 2005, 5(10):1017.
30. Zeder-Lutz G., Benito A., Van Regenmortel M.H. Active concentration measurements of recombinant biomolecules using biosensor technology. J. Mol. Recognit. 1999, 12(5):300.